Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash from Investing Activities (2017 - 2026)

Neuroone Medical Technologies filings provide 6 years of Cash from Investing Activities readings, the most recent being -$38516.0 for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 1114.63% to -$38516.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$133425.0, a 68.27% decrease, with the full-year FY2025 number at -$81742.0, up 31.99% from a year prior.
  • Cash from Investing Activities hit -$38516.0 in Q1 2026 for Neuroone Medical Technologies, up from -$40754.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $1.8 million in Q1 2023 to a low of -$3.0 million in Q3 2022.
  • Median Cash from Investing Activities over the past 5 years was -$36905.0 (2024), compared with a mean of -$47912.9.
  • Biggest five-year swings in Cash from Investing Activities: crashed 8546.56% in 2022 and later skyrocketed 2054.91% in 2023.
  • Neuroone Medical Technologies' Cash from Investing Activities stood at $15069.0 in 2022, then tumbled by 346.41% to -$37131.0 in 2023, then skyrocketed by 34.24% to -$24416.0 in 2024, then crashed by 66.92% to -$40754.0 in 2025, then grew by 5.49% to -$38516.0 in 2026.
  • The last three reported values for Cash from Investing Activities were -$38516.0 (Q1 2026), -$40754.0 (Q4 2025), and -$10607.0 (Q3 2025) per Business Quant data.